Evidence map›Paper›PMID 32011085›Full record

ArticleBJU international2020

Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy-induced oestrogen deficiency.

Katsumi Kadekawa, Naoki Kawamorita, Takahiro Shimizu, Masahiro Kurobe, Philip S Turnbull, Sundeep Chandra, Takahito Kambara, Joanna C Barton, Alan J Russell, Naoki Yoshimura

Open access · greenAbstract read
In one paragraph

Article in BJU international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Stress urinary incontinence and the forgotten female hormones.International urogynecology journal · 2022
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Katsumi KadekawaDepartment of Urology, University of Pittsburgh, Pittsburgh, PA, USA.
Naoki KawamoritaDepartment of Urology, University of Pittsburgh, Pittsburgh, PA, USA.
Takahiro ShimizuDepartment of Urology, University of Pittsburgh, Pittsburgh, PA, USA.
Masahiro KurobeDepartment of Urology, University of Pittsburgh, Pittsburgh, PA, USA.
Philip S TurnbullMuscle Metabolism DPU, GlaxoSmithKline, King of Prussia, PA, USA.
Sundeep ChandraMuscle Metabolism DPU, GlaxoSmithKline, King of Prussia, PA, USA.
Takahito KambaraPathology, Translational Medicine & Comparative Pathobiology, GlaxoSmithKline, King of Prussia, PA, USA.
Joanna C BartonMuscle Metabolism DPU, GlaxoSmithKline, King of Prussia, PA, USA.
Alan J RussellMuscle Metabolism DPU, GlaxoSmithKline, King of Prussia, PA, USA.
Naoki YoshimuraDepartment of Urology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-8070-1664
GlaxoSmithKline (United Kingdom) · GBUniversity of Pittsburgh · US

Funding

Growth Factor Gene Therapy of Stress Urinary IncontinenceR01DK107450 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YOSHIMURA, NAOKI · 2016 to 2018
$693k
GlaxoSmithKlineNIDDK NIH HHS R01 DK107450NIH HHS R01 DK107450
6 · The paper itself

Abstract

objectivesTo report the effect of a selective androgen receptor modulators (SARMs) on the urethral continence mechanisms in a rat model of stress urinary incontinence (SUI) induced by bilateral ovariectomy (OVX). MATERIALS AND

methodsFemale Sprague-Dawley rats with bilateral OVX were used. Rats were divided into five groups; sham operated, vehicle-treated OVX, low-dose SARM-treated OVX (GSK2849466A: 0.005 mg/kg/day, per os [p.o.]), high-dose SARM-treated OVX (GSK2849466A: 0.03 mg/kg/day, p.o.) and dihydrotestosterone (DHT)-treated OVX (1 mg/kg/day, subcutaneous) groups. After 4 weeks of SARM treatments or 3 weeks of DHT treatment (6 weeks after OVX), rats were subjected to evaluation of the sneeze-induced continence reflex using microtransducer-tipped catheter methods, sneeze-induced leak-point pressure, and continuous cystometry measurements, followed by histological analyses of urethral tissues.

results(i) OVX significantly impaired urethral continence function after 6 weeks to induce SUI during sneezing. (ii) Low-dose SARM treatment restored urethral baseline pressure (UBP) without affecting the amplitude of urethral response during sneezing (A-URS), partially reversing OVX-induced SUI during sneezing. (iii) High-dose SARM treatment reversed decreases in both UBP and A-URS, more effectively preventing SUI during sneezing. (iv) DHT treatment only restored A-URS without affecting UBP, partially preventing OVX-induced SUI during sneezing. (v) The high-dose SARM treatment induced hypertrophy of the striated and smooth muscle around the urethra. (vi) SARM treatment did not affect bladder function in sham or OVX rats.

conclusionTreatment with SARMs could be a more effective modality for the treatment of SUI than DHT, without affecting bladder function, by enhancing smooth- and striated muscle-mediated urethral function under stress conditions such as sneezing.

Indexed as

OvariectomyUrinary Incontinence, StressAndrogen Receptor AntagonistsAnimalsFemaleRatsRats, Sprague-DawleySneezingUrinary BladderAndrogen Receptor Antagonistsovariectomyselective androgen receptor modulatorssneeze reflexstressurethraurinary incontinence

Identifiers

PMID32011085
PMCPMC7261644
OpenAlexW3004386824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.